Related Experiment Video
Updated: Jun 1, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
[Genetic polymorphisms coding hemostasis protein synthesis and venous thromboembolic complications in Moscow
Aim:
To estimate incidence of carriage of genetic polymorphisms coding hemostasis protein synthesis in patients with venous thromboembolic complications (VTEC) and healthy subjects in Moscow population; to detect VTEC genetic prognostic factors among the polymorphisms.
Material And Methods:
A total of 111 patients with the history of deep vein thrombosis and/or pulmonary artery thromboembolism were examined. The control groups consisted of 197 healthy volunteers. Eleven polymorphisms in 7 genes coding hemostasis protein synthesis were investigated: V Leiden G1691A factor, G20210A prothrombin, C677T methylentetrahydrofolatreductase, A1298C methylentetrahydrofolatreductase, type 1 plasminogen activator inhibitor, 4G/5G promoter region, XIII V34L coagulation factor, IIIa L33P thrombocytic glycoprotein, C282Y hemochromatosis, G854A beta-fibrinogen, G455A beta-fibrinogen, C249T beta-fibrinogen.
Results:
Polymorphisms of the genes coding hemostasis protein synthesis were detected in all the patients and controls. The carriage occurred with the same frequency, respectively. By one-factor analysis, VTEC was associated with carriage of three heterozygous genotypes: V Leiden factor (p < 0.001), prothrombin (p = 0.052) and hemochromatosis (p = 0.048). Multifactor regression analysis has shown that only carriage of heterozygous polymorphism of V Leiden factor gene is a genetic prognostic factor of VTEC in Moscow population (p = 0.001, RR = 7.00, 95% CI 22-21.7).
Conclusion:
Genetic polymorphisms coding hemostasis protein synthesis are not a rare finding in Moscow population and occur in all the examinees (both patients and healthy subjects) in different combinations. Only carriage of V Leiden factor heterozygous genotype is a genetic prognostic factor of VTEC in Moscow population and is associated with a 7-fold increase of VTEC risk.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetics of Drug Metabolism: Overview
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
